NASDAQ:MRNS Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis $0.26 +0.02 (+8.07%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Marinus Pharmaceuticals Stock (NASDAQ:MRNS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MRNS alerts:Sign Up Key Stats Today's Range$0.23▼$0.2750-Day Range$0.23▼$1.8552-Week Range$0.22▼$11.26Volume579,952 shsAverage Volume1.52 million shsMarket Capitalization$14.19 millionP/E RatioN/ADividend YieldN/APrice Target$4.79Consensus RatingHold Company OverviewMarinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Read More… Marinus Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks87th Percentile Overall ScoreMRNS MarketRank™: Marinus Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 143rd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingMarinus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 2 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageMarinus Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Marinus Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.98) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marinus Pharmaceuticals is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marinus Pharmaceuticals is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarinus Pharmaceuticals has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.94% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently decreased by 4.58%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMarinus Pharmaceuticals does not currently pay a dividend.Dividend GrowthMarinus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.55 Percentage of Shares Shorted7.94% of the outstanding shares of Marinus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMarinus Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marinus Pharmaceuticals has recently decreased by 4.58%, indicating that investor sentiment is improving. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Marinus Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for MRNS on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -62% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.Percentage Held by Institutions98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Marinus Pharmaceuticals' insider trading history. Receive MRNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MRNS Stock News HeadlinesMarinus Pharmaceuticals Approves Senior Management Retention and Change in Control Severance PlansOn December 17, 2024, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced the approval of a retention plan for senior management and an amendment to tDecember 25 at 4:13 AM | americanbankingnews.comMarinus Pharmaceuticals (NASDAQ:MRNS) Earns Hold Rating from Analysts at StockNews.comDecember 23 at 2:39 AM | americanbankingnews.comAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024December 25, 2024 | True Market Insiders (Ad)Brokerages Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Target Price at $4.79December 17, 2024 | americanbankingnews.comMarinus Pharmaceuticals Reports Q3 2024 Financial Results and Strategic DevelopmentsNovember 21, 2024 | msn.comUS$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest ResultsNovember 16, 2024 | uk.finance.yahoo.comMarinus (MRNS) Initiated with a Buy at Cantor FitzgeraldNovember 14, 2024 | markets.businessinsider.comHold Rating on Marinus Pharmaceuticals Amid Strategic Uncertainty and TRUST-TSC Study SetbacksNovember 14, 2024 | markets.businessinsider.comSee More Headlines MRNS Stock Analysis - Frequently Asked Questions How have MRNS shares performed this year? Marinus Pharmaceuticals' stock was trading at $10.87 at the start of the year. Since then, MRNS stock has decreased by 97.6% and is now trading at $0.2572. View the best growth stocks for 2024 here. How were Marinus Pharmaceuticals' earnings last quarter? Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) issued its quarterly earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.01. The biopharmaceutical company had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 446.48% and a negative trailing twelve-month return on equity of 7,831.35%. When did Marinus Pharmaceuticals' stock split? Marinus Pharmaceuticals's stock reverse split before market open on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. Who are Marinus Pharmaceuticals' major shareholders? Top institutional investors of Marinus Pharmaceuticals include Suvretta Capital Management LLC (9.21%), Franklin Resources Inc. (8.54%), abrdn plc (4.83%) and GSA Capital Partners LLP (1.85%). Insiders that own company stock include Scott Braunstein, Steven Pfanstiel, Christina Shafer and Martha E Manning. View institutional ownership trends. How do I buy shares of Marinus Pharmaceuticals? Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Marinus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Marinus Pharmaceuticals investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/13/2024Today12/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRNS CUSIPN/A CIK1267813 Webwww.marinuspharma.com Phone(484) 801-4670Fax203-315-0565Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$4.79 High Stock Price Target$10.00 Low Stock Price Target$0.50 Potential Upside/Downside+1,760.7%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,400,000.00 Net Margins-446.48% Pretax Margin-446.48% Return on Equity-7,831.35% Return on Assets-120.74% Debt Debt-to-Equity RatioN/A Current Ratio1.66 Quick Ratio1.47 Sales & Book Value Annual Sales$31.47 million Price / Sales0.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book0.83Miscellaneous Outstanding Shares55,186,000Free Float52,173,000Market Cap$14.19 million OptionableOptionable Beta1.25 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:MRNS) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.